← Evidence map

ArticleCureus2025

A Randomized, Double-Blind, Placebo and Active Controlled Phase II Study to Evaluate the Safety and Efficacy of Novel Dutasteride Topical Solution (0.01%, 0.02%, and 0.05% w/v) in Male Subjects With Androgenetic Alopecia.

Veerendra Kumar Panuganti et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

The trial

NCT0742180450 enrolled2026

A Randomized, Double-Blind, Placebo and Active Controlled Phase II Study to Evaluate the Safety and Efficacy of Novel Dutasteride Topical Solution (0.01%, 0.02%, and 0.05% w/v) in Male Subjects With Androgenetic Alopecia. | OpenQuestion